Accepted for Publication: July 13, 2011.
Author Contributions: Dr Cavazos-Rehg had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Cavazos-Rehg, Spitznagel, Iguchi, and Grucza. Acquisition of data: Cavazos-Rehg. Analysis and interpretation of data: Cavazos-Rehg, Krauss, Spitznagel, Iguchi, Schootman, Cottler, Grucza, and Bierut. Drafting of the manuscript: Cavazos-Rehg, Krauss, and Spitznagel. Critical revision of the manuscript for important intellectual content: Cavazos-Rehg, Krauss, Spitznagel, Iguchi, Schootman, Cottler, Grucza, and Bierut. Statistical analysis: Krauss, Spitznagel, and Schootman. Obtained funding: Cavazos-Rehg. Administrative, technical, and material support: Cavazos-Rehg. Study supervision: Iguchi, Cottler, Grucza, and Bierut.
Financial Disclosure: Dr Bierut reported being listed as an inventor on a patent “Markers of Addiction” (US 20070258898), covering the use of certain single-nucleotide polymorphisms in determining the diagnosis, prognosis, and treatment of addiction and being a consultant for Pfizer in 2008.
Funding/Support: This work was supported by grants UL1 RR024992 and KL2 RR024994 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research and by grant K02DA021237 from the NIH. This study was also supported in part by a Career Development Award (National Institute on Drug Abuse, K01DA025733) from the NIH (Dr Cavazos-Rehg) and a Midcareer Investigator Award (K02 DA021237) from the NIH (Dr Bierut).